FULL DETAILS (Read-only)  -> Click Here to Create PDF for Current Dataset of Trial
CTRI Number  CTRI/2024/07/070131 [Registered on: 07/07/2024] Trial Registered Prospectively
Last Modified On: 11/06/2024
Post Graduate Thesis  Yes 
Type of Trial  Interventional 
Type of Study   Drug
Ayurveda 
Study Design  Single Arm Study 
Public Title of Study   A single arm clinical study :efficacy of kalyanaka guda in the management of the irritable bowel syndrome  
Scientific Title of Study   A single arm clinical study to evaluate the efficacy of kalyanaka guda in the management of irritable bowel syndrome with special reference to vatika grahani 
Trial Acronym  nil 
Secondary IDs if Any  
Secondary ID  Identifier 
NIL  NIL 
 
Details of Principal Investigator or overall Trial Coordinator (multi-center study)  
Name  Dr Mamata Godara 
Designation  PG Scholar 
Affiliation  National Institute of Ayurveda, Deemed to be University, Jaipur 
Address  Department of Kayachikitsa, National Institute of Ayurveda, Deemed to be University, Near Jorawar Singh gate, Amer Road Jaipur

Jaipur
RAJASTHAN
302002
India 
Phone  9414930150  
Fax    
Email  mamatagodara98@gmai.com  
 
Details of Contact Person
Scientific Query
 
Name  Dr Rashmi Mutha 
Designation  Assistant Professor 
Affiliation  National Institute of Ayurveda, Deemed to be University, Jaipur 
Address  Department of Kayachikitsa, National Institute of Ayurveda, Deemed to be University, Near Jorawar Singh gate, Amer Road Jaipur

Jaipur
RAJASTHAN
302002
India 
Phone  9413102151  
Fax    
Email  rashmimutha21@yahoo.com  
 
Details of Contact Person
Public Query
 
Name  Dr Rashmi Mutha 
Designation  Assistant Professor 
Affiliation  National Institute of Ayurveda, Deemed to be University, Jaipur 
Address  Department of Kayachikitsa, National Institute of Ayurveda, Deemed to be University, Near Jorawar Singh gate, Amer Road Jaipur


RAJASTHAN
302002
India 
Phone  9413102151  
Fax    
Email  rashmimutha21@yahoo.com  
 
Source of Monetary or Material Support  
National Institute of ayurved deemed to be university jaipur Rajasthan 
 
Primary Sponsor  
Name  National Institute of Ayurveda, Deemed to be University, Jaipur 
Address  Near Jorawar Singh gate, Amer Road Jaipur Jaipur RAJASTHAN 302002 India 
Type of Sponsor  Government medical college 
 
Details of Secondary Sponsor  
Name  Address 
NIL  NIL 
 
Countries of Recruitment     India  
Sites of Study  
No of Sites = 1  
Name of Principal Investigator  Name of Site  Site Address  Phone/Fax/Email 
Dr Mamata Godara  Hospital National Institute of Ayurveda, Deemed to be University, Jaipur  Department of kayachikitsa OPD No 1, 18, 22, 25
Jaipur
RAJASTHAN 
9414930150

mamatagodara98@gmai.com 
 
Details of Ethics Committee  
No of Ethics Committees= 1  
Name of Committee  Approval Status 
Institute Ethics Committee of National institute of Ayurveda, Jaipur  Approved 
 
Regulatory Clearance Status from DCGI  
Status 
Not Applicable 
 
Health Condition / Problems Studied  
Health Type  Condition 
Patients  (1) ICD-10 Condition:K582||Mixed irritable bowel syndrome. Ayurveda Condition: GRAHANIDOSHAH,  
 
Intervention / Comparator Agent  
snoIntervention/ComparatorTypeDrug-TypeProcedure NameDetails
1Intervention ArmDrugClassical(1) Medicine Name: kalyanaka guda, Reference: bhaishjaya ratnavali grahani rogadhikar 142-146, Route: Oral, Dosage Form: Avleha/Leha/Paka/Raskriya, Dose: 10(g), Frequency: bd, Bhaishajya Kal: Abhakta, Duration: 28 Days, anupAna/sahapAna: Yes(details: lukewarm water), Additional Information: -
 
Inclusion Criteria  
Age From  18.00 Year(s)
Age To  60.00 Year(s)
Gender  Both 
Details  1.Patients between the age group of 18 to 60 years.
2.Patients irrespective of sex and socio- economic status.
3.Patients having signs and symptoms (abdominal pain and altered bowel habits) of
Irritable Bowel Syndrome and Vatika Grahani like parshvavankshanruk, chiraat dukham drav shushkam tanu..punah punah srujeta varchah.. 
 
ExclusionCriteria 
Details  1. Mixed infection with parasites like round worms, hook worms etc.
2. Patients with bleeding per rectum.
3. Patients with evidence of malignancy.
4. Patients having concomitant illness like hypertension, diabetes mellitus type II,
Amoebic dysentery, Ulcerative colitis, Malabsorption syndrome,
Inflammatory Bowel Diseases & Intestinal tuberculosis, Lactase deficiency
diarrhoea.
5. Patients suffering from major systemic illness like cancer, crohn’s disease, renal
failure etc.
6. Patients who are taking corticosteroids, antidepressants, anticholinergic, or
any other drugs that may have an influence on the outcome of study.
7. Alcoholics and drug abusers.
8. Pregnant and lactating women.
9. Patients who have completed participation in any other clinical trial during the
past six months. 
 
Method of Generating Random Sequence   Not Applicable 
Method of Concealment   Not Applicable 
Blinding/Masking   Not Applicable 
Primary Outcome  
Outcome  TimePoints 
Changes in the intensity of abdominal pain and altered
bowel habits. 
At baseline and end of 28 days of treatment. 
 
Secondary Outcome  
Outcome  TimePoints 
Changes in the other symptoms(Bloating and Weakness)
of IBS.
Changes in quality of life. (QOL SF-36) 
At baseline and end of 28 days of treatment. 
 
Target Sample Size   Total Sample Size="30"
Sample Size from India="30" 
Final Enrollment numbers achieved (Total)= "Applicable only for Completed/Terminated trials"
Final Enrollment numbers achieved (India)="Applicable only for Completed/Terminated trials" 
Phase of Trial   Phase 3 
Date of First Enrollment (India)   01/08/2024 
Date of Study Completion (India) Applicable only for Completed/Terminated trials 
Date of First Enrollment (Global)  Date Missing 
Date of Study Completion (Global) Applicable only for Completed/Terminated trials 
Estimated Duration of Trial   Years="1"
Months="6"
Days="0" 
Recruitment Status of Trial (Global)   Not Applicable 
Recruitment Status of Trial (India)  Not Yet Recruiting 
Publication Details   N/A 
Individual Participant Data (IPD) Sharing Statement

Will individual participant data (IPD) be shared publicly (including data dictionaries)?  

Response - NO
Brief Summary  
INTRODUCTION:-
Ayurveda the traditional medical practice is playing an inevitable role in maintenance of health and disease prevention despite the era of modern medicine. Grahani dosha described in classical text books of Ayurveda represents a group of disorders of digestive system caused by impairment of Agni. Grahani dosha is such a disorder, wherein its significance is emphasized by its inclusion among Astha Mahagada. Grahani is located above Nabhi (umbilical region) and it is the Adhisthana (seat) of Agni. It is supported and nourished by the strength of Agni. Normally, it receives the ingested food, which is retained by it by restraining the downward movement (Grahanati). After digestion it releases the food through sides of lumen to next Ashaya i.e. Pakvashaya. In abnormal conditions due to weakness of Agni, it gets vitiated and releases food in undigested form. 
In ayurvedic literature, Grahani is one of the symptom of saman avrit apan vayu. Therefore Irritable bowel syndrome can be considered as a disorder where there is dearrangement of vata in gastrointestinal tract specially of saman vayu and apan vayu leading to symptoms of pain in abdomen and altered bowel habit. Irritable Bowel Syndrome is a functional bowel disorder characterized by abdominal pain or discomfort and altered bowel habits in the absence of detectable structural deformities. Irritable bowel syndrome symptoms tend to come and go over time and often overlap with other functional disorder such as fibromyalgia, headache, backache, and genitourinary symptoms.
The pathogenesis of Irritable bowel syndrome is poorly understood, although roles of abnormal gut motor and sensory activity, central neural dysfunction, psychological disturbances, mucosal inflammation, stress and luminal factors have been proposed. On the basis of clinical symptoms of Irritable bowel syndrome we can correlate it with Vatika Grahani in Ayurveda. 
The symptoms(gastrointestinal) present in Vatika Grahani are chirat mala pravrutti(Pass with difficulty after long time), drav(Liquid),shushkam(Dried), tanu(Thin)  aam(Undigested),phenam (Pass with froth),punah punah srujet vrchah(Frequency of stool) etc. No clear diagnostic markers exist for Irritable bowel syndrome thus the diagnosis of the disorder is based on clinical presentation. Spasmolytics, bulking and psychotropic agents are the main conventional pharmacological agents used in the Irritable bowel syndrome management.

AIM: -
To assess the effect of Kalyanaka Guda in the management of Irritable Bowel Syndrome with special reference to Vatika Grahani. 

OBJECTIVES: -
Primary objectives: Evaluation of effect of Kalyanaka Guda on the intensity of abdominal pain and altered bowel habits. 
Secondary objectives:  Evaluation of effect of Kalyanaka Guda on the other symptoms (Bloating and weakness) of IBS with special reference to Vatika Grahani and quality of life ( short form survey -36) 

HYPOTHESIS: -
NULL HYPOTHESIS(H0):- There is no difference between baseline and after treatment in the intensity of symptoms and quality of life in the patients of IBS with special reference to Vatika Grahani. 
ALTERNATIVE HYPOTHESIS(H1):- There is a difference between baseline and after treatment in the intensity of symptoms and quality of life in the patients of IBS with special reference to Vatika Grahani.

Study Design:- 
Phase -2 
• Study type-Single center, interventional, single arm, open label 
• Population-The study will be conducted on clinically diagnosed patients ‘Vatika Grahani’ and Irritable Bowel Syndrome(ROME IV criteria) selected from OPD & IPD of Department of Kayachikitsa, NIA and SSBH, Hospital Jaipur. 
• Sample- 30 patients 
• Purpose- To assess the efficacy of the trial drug 
• Masking- Open label 
• Timing- Prospective 
• Endpoint- Efficacy and safety 
• No. of groups- One 
• Duration- 28 days(4 weeks)
 
Close